These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
73 related articles for article (PubMed ID: 27393184)
1. [Not Available]. El Azizi GB; Ahid S; Ghannam I; Belaiche A; Hassar M; Cherrah Y Therapie; 2013; 68(5):303-12. PubMed ID: 27393184 [TBL] [Abstract][Full Text] [Related]
2. [Generic drugs and the consumption trends of antihypertensives in Morocco]. Berrada El Azizi G; Ahid S; Ghanname I; Belaiche A; Hassar M; Cherrah Y Therapie; 2013; 68(5):303-12. PubMed ID: 24225041 [TBL] [Abstract][Full Text] [Related]
3. Trends in antihypertensives use among Moroccan patients. Berrada El Azizi G; Ahid S; Ghanname I; Belaiche A; Hassar M; Cherrah Y Pharmacoepidemiol Drug Saf; 2012 Oct; 21(10):1067-73. PubMed ID: 22585420 [TBL] [Abstract][Full Text] [Related]
4. Factors influencing anti-asthmatic generic drug consumption in Morocco: 1999-2010. Ghanname I; Ahid S; Berrada G; Belaiche A; Hassar M; Cherrah Y Springerplus; 2014; 3():192. PubMed ID: 24790832 [TBL] [Abstract][Full Text] [Related]
5. [Consumption analyze of the antihypertensive drugs in Morocco: period 1991-2005]. Soussi-Tanani D; Alaoui K; Belaiche A; Hassar M; Cherrah Y Therapie; 2008; 63(2):129-33. PubMed ID: 18561887 [TBL] [Abstract][Full Text] [Related]
6. Trends in the use of antiasthmatic medications in Morocco (1999-2010). Ghanname I; Ahid S; Berrada G; Belaiche A; Hassar M; Cherrah Y Springerplus; 2013 Dec; 2(1):82. PubMed ID: 23519830 [TBL] [Abstract][Full Text] [Related]
7. Trends in the consumption and cost of antiepileptics in Morocco between 2008 and 2018. Cherkaoui G; Cheikh A; Razine R; Bnouhanna W; Regragui W; Benomar A; Cherrah Y Rev Epidemiol Sante Publique; 2022 Apr; 70(2):75-81. PubMed ID: 35337700 [TBL] [Abstract][Full Text] [Related]
8. Consumption and costs of antihypertensive drugs in Mexico: are diuretic agents a standing technological trajectory? Altagracia-Martínez M; Kravzov-Jinich J; Guadarrama-Atrizco MD; Rubio-Poo C; Wertheimer AI Res Social Adm Pharm; 2006 Mar; 2(1):22-37. PubMed ID: 17138499 [TBL] [Abstract][Full Text] [Related]
9. Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Bangalore S; Kumar S; Kjeldsen SE; Makani H; Grossman E; Wetterslev J; Gupta AK; Sever PS; Gluud C; Messerli FH Lancet Oncol; 2011 Jan; 12(1):65-82. PubMed ID: 21123111 [TBL] [Abstract][Full Text] [Related]
10. Pattern analysis and variations in the utilization of antihypertensive drugs in Taiwan: a six-year study. Huang LY; Shau WY; Chen HC; Su S; Yang MC; Yeh HL; Lai MS Eur Rev Med Pharmacol Sci; 2013 Feb; 17(3):410-9. PubMed ID: 23426547 [TBL] [Abstract][Full Text] [Related]
11. [Use of antihypertensive drugs in Spain, 1985-1995]. Prieto M; de Abajo FJ; Montero D; Martín-Serrano G; Madurga M; Palop R Med Clin (Barc); 1998 Feb; 110(7):247-53. PubMed ID: 9562948 [TBL] [Abstract][Full Text] [Related]
12. Role of antihypertensive therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in combination with calcium channel blockers for stroke prevention. Talbert RL J Am Pharm Assoc (2003); 2010; 50(5):e116-25. PubMed ID: 20833609 [TBL] [Abstract][Full Text] [Related]
13. Trends and patterns of five antihypertensive drug classes between 2007 and 2012 in China using hospital prescription data. Xu H; He Y; Xu L; Yan X; Dai H Int J Clin Pharmacol Ther; 2015 Jun; 53(6):430-7. PubMed ID: 25828638 [TBL] [Abstract][Full Text] [Related]
14. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Garuoliene K; Godman B; Gulbinovič J; Wettermark B; Haycox A Expert Rev Pharmacoecon Outcomes Res; 2011 Jun; 11(3):343-9. PubMed ID: 21671703 [TBL] [Abstract][Full Text] [Related]
15. Possible ways to enhance renin-angiotensin prescribing efficiency: Republic of Serbia as a case history? Kalaba M; Godman B; Vuksanović A; Bennie M; Malmström RE J Comp Eff Res; 2012 Nov; 1(6):539-49. PubMed ID: 24236473 [TBL] [Abstract][Full Text] [Related]
16. Influence of multiple initiatives in Sweden to enhance ARB prescribing efficiency following generic losartan; findings and implications for other countries. Godman B; Wettermark B; Miranda J; Bennie M; Martin A; Malmström RE Int J Clin Pract; 2013 Sep; 67(9):853-62. PubMed ID: 23560825 [TBL] [Abstract][Full Text] [Related]
17. Anti-hypertensive drug utilization in Continental Portugal (1999-2004). Furtado C; Pinto M Rev Port Cardiol; 2006 Mar; 25(3):273-92. PubMed ID: 16789402 [TBL] [Abstract][Full Text] [Related]
18. How well have practices followed guidelines in prescribing antihypertensive drugs: the role of health insurance. Guo JD; Liu GG; Christensen DB; Fu AZ Value Health; 2003; 6(1):18-28. PubMed ID: 12535235 [TBL] [Abstract][Full Text] [Related]
19. Use and cost of branded and generic drugs in patients with coronary heart disease--results from a prospective survey of 1008 patients in two London hospitals. Corp EV; Antoniou S; Wright PG; Khachi H; Vercaeren S; Wald DS QJM; 2009 Dec; 102(12):843-9. PubMed ID: 19828644 [TBL] [Abstract][Full Text] [Related]
20. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system. Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]